Day: January 8, 2025

NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with...

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST). The presentation will be webcast live and may be accessed through C4T’s website on the Events & Presentations page. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation. About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new...

• Provides 2025 Annual Guidance of $178 – $182 Million in Revenue and $38 – $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance• Expects to Achieve 2024 Guidance of $158 – $162 Million in Revenue and $32 – $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million• Aiming to Secure New Business Development and M&A Transactions During 2025 that Leverage Overall Financial Strength and Existing Commercial Infrastructure to Accelerate Long-Term Growth• Expansion of Plasma Collection Operations with Opening of a Third Center by End of Q1 2025• Based on Positive Feedback from U.S. FDA, Kamada Plans to Reduce Inhaled AAT Clinical Study Sample Size to Approximately 180 Patients; Interim Futility Analysis...

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30 AM EST). A live webcast of the presentation will be available on the Investors section of the Company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc.iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the...

VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) provides an update on the progress at its Terronera project. The Terronera project experienced delivery delays during December of critical path structural steel components required for the lower platform construction and tailing filter area installations. This has adversely impacted overall project productivity and expected commissioning timelines. In light of these delays, management reduced the site workforce over the holiday season from December 20, 2024 to January 6, 2025 as a cost saving measure. The lower platform construction and filter area installation is the critical path to wet commissioning, which is now expected in early Q2 2025. Following Mexico’s lifting...

Filing follows successful completion of the independent audit for the year ended 30 June 2024 Singapore, Jan. 08, 2025 (GLOBE NEWSWIRE) — SINGAPORE, January 8, 2025 (GLOBE NEWSWIRE) — noco-noco Inc (OTCMKTS: NCNCF), today announced that the delayed filing of their 2024 Annual Report on Form 20-F has now been remedied and filed on December 26, 2024, as amended on January 8, 2025. This follows the successful completion of the independent audit for the year ended 30 June 2024. The delay in the filing of the Form 20-F was due to a number of strategic changes implemented to drive operational efficiency, which included a change in auditors. Upon filing the Form 20-F, as amended, the Company is now compliant in its filings and has also moved up to the Pink Tier on the OTC Markets. The Company has appealed the Hearing Panel’s determination...

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announced preliminary gold and copper production results for the three and twelve months ended December 31, 2024, with both mines achieving annual production guidance. “We ended 2024 on a strong note, with Ada Tepe delivering its highest quarterly production of the year, and Chelopech continuing its long track record of performance,” said David Rae, President and Chief Executive Officer. “I’m pleased to report that 2024 marks the tenth consecutive year we have achieved our gold production guidance, which is a remarkable milestone in the mining industry and a testament to our strengths as operators.” Preliminary Production Highlights Preliminary results for the fourth quarter and full-year of 2024 are provided in the table below:  Ore...

Castellum, Inc.’s SBA Protégés Successfully Onboard to SeaPort-NxG ContractCastellum, Inc. (NYSE-American: CTM) (“Castellum”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that it has successfully helped onboard its two Small Business Administration (“SBA”) approved mentor-protégé companies (“Mentor-Protégé”), Epic Systems, Inc. (“Epic”) and Krilla Kaleiwahea, LLC (“K2”), to its Seaport Next Generation contract (“SeaPort-NxG”) via rolling admissions II – https://castellumus.com/VIENNA, Va., Jan. 08, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum”), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that it has successfully helped onboard...

HOUSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today provided operational and financial updates on recent developments.Recently signed a purchase and sale agreement (“PSA”) to sell a non-core interest in Garden Banks Blocks 385 and 386 which included latest net production of approximately 195 barrels of oil equivalent per day (“Boe/d”) (72% oil) for $12.3 million; Announces that the West Delta 73 field, which W&T acquired in January 2024, is expected to come back online by mid-second quarter 2025; Announces that the Main Pass 108 and 98 fields, which have been shut in since June 2024, are expected to return to production by early second quarter of 2025.Net production at these fields averaged a combined 6.1 million cubic feet of natural gas equivalent per day...